Peter Hersey

List of Publications by Year in descending order

78 papers	13,837 citations	76326 40 h-index	79698 73 g-index
83 all docs	83 docs citations	83 times ranked	20482 citing authors

#	Article	IF	Citations
1	Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma. Journal of Investigative Dermatology, 2022, 142, 1444-1455.e10.	0.7	11
2	Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells. Cancers, 2022, 14, 323.	3.7	6
3	Re: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. European Journal of Cancer, 2022, 162, 241-242.	2.8	0
4	Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma. Journal of Investigative Dermatology, 2022, 142, 1004-1006.	0.7	2
5	Sex bias of females in survival from cancer and infections. Is X the answer?. British Journal of Cancer, 2021, 124, 1184-1186.	6.4	5
6	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 2021, 144, 182-191.	2.8	57
7	DPP9: Comprehensive In Silico Analyses of Loss of Function Gene Variants and Associated Gene Expression Signatures in Human Hepatocellular Carcinoma. Cancers, 2021, 13, 1637.	3.7	9
8	Associations between DPP9 expression, survival and gene expression signature in human hepatocellular carcinoma: Comprehensive in silico analyses. FASEB Journal, 2021, 35, .	0.5	1
9	Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers. Frontiers in Genetics, 2021, 12, 680633.	2.3	14
10	Transcriptional Reprogramming and Constitutive PD-L1 Expression in Melanoma Are Associated with Dedifferentiation and Activation of Interferon and Tumour Necrosis Factor Signalling Pathways. Cancers, 2021, 13, 4250.	3.7	9
11	A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma. Journal of Investigative Dermatology, 2021, 141, 2238-2249.e12.	0.7	7
12	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 2021, 157, 391-402.	2.8	13
13	Study of the Female Sex Survival Advantage in Melanomaâ€"A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts. Cancers, 2020, 12, 2082.	3.7	16
14	EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma. Journal of Investigative Dermatology, 2020, 140, 2442-2454.e5.	0.7	46
15	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
16	Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. Frontiers in Immunology, 2020, 11, 372.	4.8	20
17	Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma?. Pigment Cell and Melanoma Research, 2020, 33, 660-670.	3.3	14
18	Coâ€targeting bromodomain and extraâ€terminal proteins and MCL1 induces synergistic cell death in melanoma. International Journal of Cancer, 2020, 147, 2176-2189.	5.1	16

#	Article	IF	Citations
19	A Th1/IFNÎ³ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 1725-1735.	7.0	13
20	Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive longâ€‘term BRAF inhibition. International Journal of Oncology, 2020, 56, 1429-1441.	3.3	10
21	Abstract LB-177: BET and CDK9 protein inhibitors: Novel epigenetic therapy to synergistically kill human melanoma cells. , 2020, , .		0
22	Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer. Epigenomics, 2019, 11, 732-737.	2.1	11
23	Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. Trends in Immunology, 2019, 40, 328-344.	6.8	160
24	Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming. Clinical Epigenetics, 2019, 11, 43.	4.1	53
25	Magnolol induces cell death through PI3K/Aktâ€mediated epigenetic modifications boosting treatment of BRAFâ€ and NRASâ€mutant melanoma. Cancer Medicine, 2019, 8, 1186-1196.	2.8	16
26	Shedding light on dabrafenib-induced fevers in patients with melanoma. Lancet Oncology, The, 2019, 20, 1637-1638.	10.7	2
27	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clinical Cancer Research, 2018, 24, 4960-4967.	7.0	222
28	Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunology, Immunotherapy, 2018, 67, 563-573.	4.2	50
29	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-NaÃ¯ve Melanoma Patients and Expand Significantly During Antiâ€“PD-1 Treatment. Clinical Cancer Research, 2018, 24, 3036-3045.	7.0	297
30	Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers. Clinical Cancer Research, 2018, 24, 1090-1102.	7.0	16
31	HDAC inhibitors restore BRAFâ€inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. International Journal of Cancer, 2018, 142, 1926-1937.	5.1	48
32	Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma. IScience, 2018, 4, 312-325.	4.1	69
33	SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling. Nature Communications, 2018, 9, 3440.	12.8	80
34	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 916-929.	10.7	131
35	Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget, 2018, 9, 8206-8222.	1.8	54
36	Abstract 5833: Escape form adaptive drug tolerance through OGT and TET1 mediated H3K4me3 remodeling in MAPKi resistant melanoma. , 2018, , .		0

#	Article	IF	Citations
37	A preliminary evaluation of cytotoxicity, antihyperglycemic and antinociceptive activity of Polygonum hydropiper L. ethanolic leaf extract. Clinical Phytoscience, 2017, 2, .	1.6	9
38	Whole-genome landscapes of major melanoma subtypes. Nature, 2017, 545, 175-180.	27.8	1,068
39	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. New England Journal of Medicine, 2017, 376, 2211-2222.	27.0	1,087
40	Epigenetic modulation in cancer immunotherapy. Current Opinion in Pharmacology, 2017, 35, 48-56.	3.5	50
41	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA - Journal of the American Medical Association, 2016, 315, 1600.	7.4	857
42	EZH2 as a mediator of treatment resistance in melanoma. Pigment Cell and Melanoma Research, 2016, 29, 500-507.	3.3	37
43	Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma. Neoplasia, 2016, 18, 121-132.	5.3	43
44	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of Clinical Oncology, 2016, 34, 1510-1517.	1.6	627
45	Abstract B34: Global histone modifications define early stress induced drug tolerance in cancer. , 2016, , .		0
46	Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Oncotarget, 2015, 6, 27023-27036.	1.8	83
47	Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-Î¹B. PLoS ONE, 2015, 10, e0123410.	2.5	181
48	Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. Cancers, 2015, 7, 1959-1982.	3.7	32
49	Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. Future Oncology, 2015, 11, 133-140.	2.4	9
50	Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696.	28.9	2,562
51	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitorâ€“Treated Melanoma Patients. Clinical Cancer Research, 2015, 21, 3140-3148.	7.0	120
52	Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 2015, 28, 884-894.	5.5	37
53	<scp>EZH</scp>2: an emerging role in melanoma biology and strategies for targeted therapy. Pigment Cell and Melanoma Research, 2015, 28, 21-30.	3.3	47
54	Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget, 2015, 6, 21507-21521.	1.8	72

#	Article	IF	Citations
55	TP53 Codon 72 Polymorphisms and Lung Cancer Risk in the Bangladeshi Population. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3493-3498.	1.2	10
56	The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells. Journal of Investigative Dermatology, 2014, 134, 2795-2805.	0.7	55
57	Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress. Journal of Investigative Dermatology, 2014, 134, 488-497.	0.7	66
58	Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology, 2014, 8, 544-554.	4.6	98
59	Control of <scp>NF</scp>â€<scp>kB</scp> activity in human melanoma by bromodomain and extraâ€terminal protein inhibitor <scp>I</scp>â€<scp>BET</scp>151. Pigment Cell and Melanoma Research, 2014, 27, 1126-1137.	3.3	75
60	Score Based Risk Assessment of Lung Cancer and its Evaluation for Bangladeshi People. Asian Pacific Journal of Cancer Prevention, 2014, 15, 7021-7027.	1.2	5
61	Safety and Tumor Responses with Lambrolizumab (Antiâ€“PD-1) in Melanoma. New England Journal of Medicine, 2013, 369, 134-144.	27.0	3,128
62	A Focus on PD-L1 in Human Melanoma. Clinical Cancer Research, 2013, 19, 514-516.	7.0	17
63	BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 2013, 133, 509-517.	0.7	156
64	OBATOCLAX and ABT-737 Induce ER Stress Responses in Human Melanoma Cells that Limit Induction of Apoptosis. PLoS ONE, 2013, 8, e84073.	2.5	29
65	Early Detection of Lung Cancer Risk Using Data Mining. Asian Pacific Journal of Cancer Prevention, 2013, 14, 595-598.	1.2	56
66	Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. Melanoma Research, 2012, 22, 244-251.	1.2	30
67	Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737. Clinical Cancer Research, 2012, 18, 783-795.	7.0	98
68	Contrasting Effects of Nutlin-3 on TRAIL- and Docetaxel-Induced Apoptosis Due to Upregulation of TRAIL-R2 and Mcl-1 in Human Melanoma Cells. Molecular Cancer Therapeutics, 2010, 9, 3363-3374.	4.1	30
69	Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma. Journal of Clinical Oncology, 2009, 27, 2823-2830.	1.6	517
70	Treatment combinations targeting apoptosis to improve immunotherapy of melanoma. Cancer Immunology, Immunotherapy, 2009, 58, 1749-1759.	4.2	32
71	Up-regulation of Mcl-1 Is Critical for Survival of Human Melanoma Cells upon Endoplasmic Reticulum Stress. Cancer Research, 2008, 68, 6708-6717.	0.9	129
72	Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1. Clinical Cancer Research, 2007, 13, 4934-4942.	7.0	168

#	Article	IF	Citations
73	Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma. Journal of Clinical Oncology, 2007, 25, 2540-2545.	1.6	95
74	Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Modern Pathology, 2007, 20, 416-426.	5.5	169
75	Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene, 2004, 23, 4060-4067.	5.9	169
76	Adjuvant Immunotherapy of Patients With High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial. Journal of Clinical Oncology, 2002, 20, 4181-4190.	1.6	144
77	Factors related to the presentation of patients with thick primary melanomas. Medical Journal of Australia, 1991, 154, 583-587.	1.7	75
78	Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Cancer Immunology, Immunotherapy, 1987, 25, 257-65.	4.2	62